Medasense will be participating in the hybrid ISA 2020 conference, including a feature lecture by
Treating Pain is at the
Heart of Medicine
Medasense is the developer of a unique technology that objectively monitors and quantifies the patient’s pain response level using artificial intelligence algorithms and a proprietary noninvasive sensor platform.
NOL technology is used to optimize pain management in critical care settings, where anaesthetized patients are unable to communicate, and recent evidence shows that postoperative pain scores can be reduced by 33% following NOL-guided surgery.1
Interface connectivity is enabled with Philips patient monitors, enabling a consolidated view of changes in pain response level alongside vital signs.
The technology is distributed across Europe exclusively by Medtronic, and by leading partners in other regions.
DISTRIBUTION MAP
nol technology
Eliminate guesswork and meet clinical challenges in assessing pain and improving analgesia.
CLINICAL EVIDENCE
Recent clinical studies have demonstrated the impact that NOL monitoring has on patient safety,2 outcomes and savings,3 including 33% reduction in reported postoperative pain.1
MEDASENSE ACADEMY
Welcome to our online and customized education and training program for clinicians and commercial partners.
The essence of Medasense: Guiding critical care clinicians for optimal pain care
Meeting the challenge of intraoperative pain monitoring
Leading clinicians on the importance of monitoring the patient’s pain response level
Clinical Collaborations
REFERENCES:
1. Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L.,
Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane
anaesthesia: a randomised controlled trial. British Journal of Anaesthesia [In Press]
2. Meijer, F., Martini, C., Broens, S., Boon, M., Niesters, M., Aarts, L., Olofsen, E., van Velzen, M., Dahan, A. (2019). Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology, 130(5), 745-755. doi:10.1097/ALN.0000000000002634
3. Saunders R., Weissbrod R. (2020). Cost benefit of personalizing intraoperative pain management. Presented at ISPOR Virtual Conference, May 2020